Opportunity Information: Apply for PAR 24 107
Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional), funding opportunity number PAR-24-107, is an NIH small business grant opportunity focused on building practical, commercializable tools or platforms that make it easier to stand up and operate regional genomic medicine eConsult services. In plain terms, NIH is looking for Small Business Innovation Research (SBIR) projects that can help clinicians and health systems access genomic expertise through an electronic consult model, especially in settings where local genetics specialists may be limited. The emphasis is not just on research for research's sake, but on developing solutions with a clear path to real-world use and commercialization that can support regional-scale service delivery.
The program uses the R41/R42 mechanisms, meaning applicants can propose a phased SBIR approach. Phase I (R41) typically supports early feasibility and proof of concept work, while Phase II (R42) supports further development, validation, and steps toward deployment and commercialization. The notice indicates "Clinical Trial Optional," which means applicants may include a clinical trial if it is appropriate for evaluating their solution, but a clinical trial is not required to apply. The funding instrument is a grant, the opportunity category is discretionary, and it falls under NIH's health research and development mission (CFDA 93.172).
Eligibility is limited to small businesses, which is consistent with SBIR funding. The notice also makes clear that non-U.S. entities (foreign organizations) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible either. However, foreign components may be allowed in certain circumstances as defined under the NIH Grants Policy Statement, which generally means limited, well-justified foreign involvement could be permissible if it is essential to the project and meets NIH policy requirements. The issuing agency is the National Institutes of Health, and the original closing date listed for this opportunity is 2024-05-30. The posting indicates the opportunity was created on 2024-01-09, while specific figures such as the award ceiling and expected number of awards are not provided in the supplied source data.
Overall, the opportunity is geared toward small companies that can produce scalable, implementable solutions enabling genomic medicine eConsult workflows at a regional level. That could include, for example, software, clinical decision support tools, interoperability approaches, workflow automation, documentation and triage systems, or other service-enabling infrastructure that helps connect ordering clinicians with genomic expertise, standardize consult processes, and support adoption across multiple sites while meeting the practical needs of healthcare delivery and eventual commercialization.Apply for PAR 24 107
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2024-01-09.
- Applicants must submit their applications by 2024-05-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the PAR-24-107 funding opportunity?
PAR-24-107, titled "Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)," is an NIH Small Business Innovation Research (SBIR) grant opportunity focused on developing practical tools or platforms that make it easier to establish and operate regional genomic medicine eConsult services.
What problem is NIH trying to solve with this SBIR topic?
The opportunity targets barriers to accessing genomic expertise in routine care, especially where local genetics specialists are limited. The goal is to support electronic consult (eConsult) models that help clinicians and health systems connect to genomic medicine expertise through scalable, regional service delivery.
What kinds of projects are a fit for this opportunity?
Projects should develop commercializable solutions that enable genomic medicine eConsult workflows at a regional level. Examples mentioned or implied include software platforms, clinical decision support tools, interoperability approaches, workflow automation, documentation and triage systems, and other service-enabling infrastructure that supports standardized consult processes and adoption across multiple sites.
Is this opportunity focused on research, product development, or both?
It emphasizes development of practical solutions with a clear path to real-world use and commercialization. While research and development are part of SBIR, the intent here is not research for its own sake, but building implementable tools or platforms that can be deployed and sustained in healthcare delivery settings.
What does "regional genomic medicine eConsult services" mean in plain terms?
It refers to an electronic consult model where clinicians can obtain genomic medicine input (such as guidance or expertise) through an electronic workflow, with services designed to operate across a region and support multiple sites or health systems, rather than relying only on local, on-site genetics specialists.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with the SBIR program requirements.
Can a non-U.S. (foreign) company apply?
No. The notice indicates non-U.S. entities (foreign organizations) are not eligible to apply.
Can a U.S. organization include a non-U.S. component?
Non-U.S. components of U.S. organizations are not eligible. However, foreign components may be allowed in certain circumstances under the NIH Grants Policy Statement, typically when the foreign involvement is limited, well-justified, essential to the project, and meets NIH policy requirements.
What funding mechanisms are used for this opportunity?
The opportunity uses the NIH SBIR R41/R42 mechanisms, which support a phased approach: Phase I (R41) generally covers early feasibility and proof of concept, and Phase II (R42) generally supports further development, validation, and steps toward deployment and commercialization.
What is the difference between Phase I (R41) and Phase II (R42) in this announcement?
Phase I (R41) is typically aimed at feasibility work and proof of concept. Phase II (R42) typically supports more advanced development and validation, along with activities that move the solution closer to deployment and commercialization.
Are clinical trials required?
No. The opportunity is labeled "Clinical Trial Optional," meaning a clinical trial may be included if it is appropriate for evaluating the solution, but a clinical trial is not required to apply.
What is the funding instrument and opportunity category?
The funding instrument is a grant, and the opportunity category is discretionary.
Which agency is issuing this opportunity?
The issuing agency is the National Institutes of Health (NIH).
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.172.
What is the funding opportunity number?
The funding opportunity number is PAR-24-107.
What was the original closing date listed for this opportunity?
The original closing date listed is 2024-05-30.
When was the opportunity created (posted)?
The posting indicates the opportunity was created on 2024-01-09.
Does the provided information include an award ceiling or expected number of awards?
No. The supplied source data does not provide figures for an award ceiling or the expected number of awards.
What kinds of outcomes is NIH looking for from funded projects?
Based on the description, NIH is looking for scalable, implementable solutions that support regional-scale genomic medicine eConsult service delivery and have a clear commercialization pathway, enabling broader adoption across multiple care sites while meeting practical healthcare workflow needs.
Browse more opportunities from the same category: Health
Next opportunity: Limited Competition: Alcohol-associated Hepatitis Clinical Network Integrated Treatment Clinical Trials Clinical Centers (U01-Clinical Trial required)
Previous opportunity: ERDC Broad Agency Announcement
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 24 107
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 24 107) also looked into and applied for these:
| Funding Opportunity |
|---|
| NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA HG 24 013 Funding Number: RFA HG 24 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) Apply for PAR 24 096 Funding Number: PAR 24 096 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) Apply for PAR 24 095 Funding Number: PAR 24 095 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) Apply for PAR 24 097 Funding Number: PAR 24 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) Apply for PAR 24 098 Funding Number: PAR 24 098 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed) Apply for PAR 24 129 Funding Number: PAR 24 129 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) Apply for PAR 24 112 Funding Number: PAR 24 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed) Apply for PAR 24 111 Funding Number: PAR 24 111 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Evaluation and Coordinating Center for the AHRQ/PCORI Learning Health System Embedded Scientist Training and Research Centers (U18) Apply for RFA HS 24 002 Funding Number: RFA HS 24 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,000,000 |
| Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed) Apply for RFA AI 24 003 Funding Number: RFA AI 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| USAID/Kenya and East Africa Global Health Security (GHS) Activity Apply for 72061524RFI00002 Funding Number: 72061524RFI00002 Agency: Kenya USAID-Nairobi Category: Health Funding Amount: Case Dependent |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) Apply for PAR 24 099 Funding Number: PAR 24 099 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) Apply for PAR 24 100 Funding Number: PAR 24 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Localization in Health Apply for 620 24 0002 Funding Number: 620 24 0002 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) Apply for PAR 24 124 Funding Number: PAR 24 124 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) Apply for PAR 24 116 Funding Number: PAR 24 116 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) Apply for PAR 24 115 Funding Number: PAR 24 115 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 24 123 Funding Number: PAR 24 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Strengthening Local Health Security Apply for 72044024RFA00001 Funding Number: 72044024RFA00001 Agency: USAID-VIETNAM Category: Health Funding Amount: $21,500,000 |
| Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) Apply for PAR 24 147 Funding Number: PAR 24 147 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 24 107", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.